{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:46:33Z","timestamp":1757706393815},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7-8","license":[{"start":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T00:00:00Z","timestamp":1557446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T00:00:00Z","timestamp":1557446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00508-019-1505-6","type":"journal-article","created":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T14:05:05Z","timestamp":1557497105000},"page":"185-189","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of the clinical relevance of vancomycin for the treatment of Lyme disease"],"prefix":"10.1007","volume":"135","author":[{"given":"Gary P.","family":"Wormser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan G.","family":"Barbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,10]]},"reference":[{"key":"1505_CR1","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1086\/508667","volume":"43","author":"GP Wormser","year":"2006","unstructured":"Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, et\u00a0al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: Clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43:1089\u2013134.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"1505_CR2","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1474-4422(08)70119-4","volume":"7","author":"U Lj\u00f8stad","year":"2008","unstructured":"Lj\u00f8stad U, Skogvoll E, Eikeland R, Midgard R, Skarpaas T, Berg A, et al. Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: A multicenter, non-inferiority, double-blind, randomized trial. Lancet Neurol. 2008;7(8):690\u20135.","journal-title":"Lancet Neurol"},{"key":"1505_CR3","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S1474-4422(08)70120-0","volume":"7","author":"GP Wormser","year":"2008","unstructured":"Wormser GP, Halperin JJ. Oral doxycycline for neuroborreliosis. Lancet Neurol. 2008;7:665\u20136.","journal-title":"Lancet Neurol"},{"key":"1505_CR4","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1128\/AAC.40.11.2632","volume":"40","author":"RJ Kazragis","year":"1996","unstructured":"Kazragis RJ, Dever LL, Jorgensen JH, Barbour AG. In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the mouse brain and other sites. Antimicrob Agents Chemother. 1996;40:2632\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"1505_CR5","doi-asserted-by":"publisher","first-page":"e01201-18","DOI":"10.1128\/AAC.01201-18","volume":"62","author":"X Wu","year":"2018","unstructured":"Wu X, Sharma B, Niles S, O\u2019Connor K, Schilling R, Matluck N, et al. Identifying vancomycin as an effective antibiotic for killing Borrelia burgdorferi. Antimicrob Agents Chemother. 2018;62:e01201-18. https:\/\/doi.org\/10.1128\/AAC.01201-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"1505_CR6","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.bpj.2016.12.039","volume":"112","author":"MW Harman","year":"2017","unstructured":"Harman MW, Hamby AE, Boltyanskiy R, Belperron AA, Bockenstedt LK, Kress H, et\u00a0al. Vancomycin reduces cell wall stiffness and slows swim speed of the Lyme disease bacterium. Biophys\u00a0J. 2017;112:746\u201354.","journal-title":"Biophys J"},{"key":"1505_CR7","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1128\/AAC.37.5.1115","volume":"37","author":"LL Dever","year":"1993","unstructured":"Dever LL, Jorgensen JH, Barbour AG. In vitro activity of vancomycin against the spirochete Borrelia burgdorferi. Antimicrob Agents Chemother. 1993;37:1115\u201321.","journal-title":"Antimicrob Agents Chemother"},{"key":"1505_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0924-8579(00)00342-3","volume":"17","author":"K-P Hunfeld","year":"2001","unstructured":"Hunfeld K\u2011P, Weigand J, Wichelhaus TA, Kekoukh E, Kraiczy P, Brade V. In vitro activity of mezlocillin, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin, and fusidic acid against Borrelia burgdorferi. Int J Antimicrob Agents. 2001;17:203\u20138.","journal-title":"Int J Antimicrob Agents"},{"key":"1505_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0378-1119(02)01146-0","volume":"303","author":"ML Sartakova","year":"2003","unstructured":"Sartakova ML, Dobrikova EY, Terekhova DA, Devis R, Bugrysheva JV, Morozova OV, et al. Novel antibiotic-resistance markers in pGK-12-derived vectors for Borrelia burgdorferi. Gene. 2003;303:131\u20137.","journal-title":"Gene"},{"key":"1505_CR10","doi-asserted-by":"publisher","first-page":"4616","DOI":"10.1128\/AAC.00864-15","volume":"59","author":"B Sharma","year":"2015","unstructured":"Sharma B, Brown AV, Matluck NE, Hu LT, Lewis K. Borrelia burgdorferi, the causative agent of Lyme disease, forms drug-tolerant persistor cells. Antimicrob Agents Chemother. 2015;59:4616\u201324.","journal-title":"Antimicrob Agents Chemother"},{"key":"1505_CR11","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 28th\u00a0ed. Wayne: CLSI; 2018. CLSI Supplement M100.","edition":"28"},{"issue":"4","key":"1505_CR12","first-page":"694","volume":"19","author":"FR Bruniera","year":"2015","unstructured":"Bruniera FR, Ferreira FM, Saviolli LR, Bacci MR, Feder D, da Luz Gon\u00e7alves Pedreira M, et\u00a0al. The use of vancomycin with its therapeutic and adverse effects: A review. Eur Rev Med Pharmacol Sci. 2015;19(4):694\u2013700.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1505_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/9781118960608.fbm00308","volume-title":"Bergey\u2019s manual of systematics of archaea and bacteria","author":"AG Barbour","year":"2018","unstructured":"Barbour AG. Borreliaceae. In: Whitman WB, Rainey F, K\u00e4mpfer P, Trujillo M, Chun J, DeVos P, Hedlund B, Dedysh S, editors. Bergey\u2019s manual of systematics of archaea and bacteria. 2018. https:\/\/doi.org\/10.1002\/9781118960608.fbm00308."},{"key":"1505_CR14","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1093\/jac\/dks142","volume":"67","author":"F Docobo-P\u00e9rez","year":"2012","unstructured":"Docobo-P\u00e9rez F, L\u00f3pez-Rojas R, Dom\u00ednguez-Herrera J, Jim\u00e9nez-Mejias ME, Pichardo C, Ib\u00e1\u00f1ez-Mart\u00ednez J, et al. Efficacy of linezolid versus a pharmacodynamically optimized vancomycin therapy in an experimental pneumonia model caused by methicillin-resistant Staphylococcus aureus. J\u00a0Antimicrob Chemother. 2012;67:1961\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"1505_CR15","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1203\/PDR.0b013e3181994a53","volume":"65","author":"FX Placencia","year":"2009","unstructured":"Placencia FX, Kong L, Weisman LE. Treatment of methicillin-resistant Staphylococcus aureus in neonatal mice: Lysostaphin versus vancomycin. Pediatr Res. 2009;65(4):420\u20134.","journal-title":"Pediatr Res"},{"key":"1505_CR16","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00281-17","author":"AJ Lepak","year":"2017","unstructured":"Lepak AJ, Zhao M, Andes DR. Comparative pharmacodynamics of telavancin and vancomycin in the neutropenic murine thigh and lung infection models against Staphylococcus aureus. Antimicrob Agents Chemother. 2017; https:\/\/doi.org\/10.1128\/AAC.00281-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"1505_CR17","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1128\/AAC.03710-14","volume":"59","author":"A Louie","year":"2015","unstructured":"Louie A, Boyne MT II, Patel V, Huntley C, Liu W, Fikes S, et\u00a0al. Pharmacodynamic evaluation of the activities of six parenteral vancomycin products available in the United States. Antimicrob Agents Chemother. 2015;59:622\u201332.","journal-title":"Antimicrob Agents Chemother"},{"key":"1505_CR18","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ijantimicag.2016.09.011","volume":"48","author":"J Dominguez-Herrera","year":"2016","unstructured":"Dominguez-Herrera J, Lopez-Rojas R, Smani Y, Labrador-Herrera G, Pachon J. Efficacy of ceftaroline versus vancomycin in an experimental foreign-body and systemic infection model caused by bio-film producing methicillin-resistant Staphylococcus epidermidis. Int J Antimicrob Agents. 2016;48:661\u20135.","journal-title":"Int J Antimicrob Agents"},{"key":"1505_CR19","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1128\/AAC.34.10.1869","volume":"34","author":"WE Peetermans","year":"1990","unstructured":"Peetermans WE, Hoogeterp JJ, Hazekamp-van Dokkum A\u2011M, van den Broek P, Mattie H. Anti-staphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection. Antimicrob Agents Chemother. 1990;34:1869\u201374.","journal-title":"Antimicrob Agents Chemother"},{"key":"1505_CR20","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","volume":"43","author":"PA Moise","year":"2004","unstructured":"Moise PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus respiratory tract infections. Clin Pharmacokinet. 2004;43:925\u201342.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1505_CR21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/cid\/ciy557","volume":"68","author":"G Sakoulas","year":"2019","unstructured":"Sakoulas G, Geriak M, Nizet V. Is a reported penicillin allergy sufficient grounds to forego the multidimensional antimicrobial benefits of \u03b2\u2011lactam antibiotics? Clin Infect Dis. 2019;68(1):157\u201364. https:\/\/doi.org\/10.1093\/cid\/ciy557.","journal-title":"Clin Infect Dis"},{"key":"1505_CR22","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1128\/AAC.01088-08","volume":"53","author":"A Forouzesh","year":"2009","unstructured":"Forouzesh A, Moise PA, Sakoulas G. Vancomycin ototoxicity: A\u00a0re-evaluation in an era of increasing doses. Antimicrob Agents Chemother. 2009;53:483\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"1505_CR23","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s40262-017-0548-y","volume":"56","author":"JE Beach","year":"2017","unstructured":"Beach JE, Perrott J, Turgeon RD, Ensom MHH. Penetration of vancomycin into the cerebrospinal fluid: A systematic review. Clin Pharmacokinet. 2017;56(12):1479\u201390.","journal-title":"Clin Pharmacokinet"},{"key":"1505_CR24","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1001\/jama.1992.03480100070033","volume":"267","author":"BJ Luft","year":"1992","unstructured":"Luft BJ, Steinman CR, Neimark HC, Muralidhar B, Rush T, Finkel MF, et\u00a0al. Invasion of the central nervous system by Borrelia burgdorferi in acute disseminated infection. JAMA. 1992;267:1364\u20137.","journal-title":"JAMA"},{"key":"1505_CR25","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1056\/NEJM199707313370501","volume":"337","author":"RJ Dattwyler","year":"1997","unstructured":"Dattwyler RJ, Luft BJ, Kunkel MJ, Finkel MF, Wormser GP, Rush TJ, et\u00a0al. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. N\u00a0Engl J Med. 1997;337:289\u201394.","journal-title":"N Engl J Med"},{"key":"1505_CR26","doi-asserted-by":"publisher","first-page":"697","DOI":"10.7326\/0003-4819-138-9-200305060-00005","volume":"138","author":"GP Wormser","year":"2003","unstructured":"Wormser GP, Ramanathan R, Nowakowski J, McKenna D, Holmgren D, Visintainer P, et al. Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003;138:697\u2013704.","journal-title":"Ann Intern Med"},{"key":"1505_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0002-9343(03)00308-5","volume":"115","author":"J Nowakowski","year":"2003","unstructured":"Nowakowski J, Nadelman RB, Sell R, McKenna D, Cavaliere FC, Holmgren D, et al. Long-term follow-up of patients with culture-confirmed Lyme disease. Am J Med. 2003;115:91\u20136.","journal-title":"Am J Med"},{"key":"1505_CR28","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1093\/cid\/civ735","volume":"61","author":"E Weitzner","year":"2015","unstructured":"Weitzner E, McKenna D, Nowakowski J, Scavarda C, Dornbush R, Bittker S, et al. Long-term assessment of post-treatment symptoms in patients with culture-confirmed early Lyme disease. Clin Infect Dis. 2015;61:1800\u20136.","journal-title":"Clin Infect Dis"},{"key":"1505_CR29","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1128\/CMR.00004-09","volume":"22","author":"GP Wormser","year":"2009","unstructured":"Wormser GP, Schwartz I. Antibiotic treatment of animals infected with Borrelia burgdorferi. Clin Microbiol Rev. 2009;22:387\u201395.","journal-title":"Clin Microbiol Rev"},{"key":"1505_CR30","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.diagmicrobio.2018.06.007","volume":"92","author":"GP Wormser","year":"2018","unstructured":"Wormser GP, O\u2019Connell S, Pachner AR, Schwartz I, Shapiro ED, Stanek G, et\u00a0al. Critical analysis of a\u00a0doxycycline treatment trial of rhesus macaques infected with Borrelia burgdorferi. Diagn Microbiol Infect Dis. 2018;92:183\u20138.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"1505_CR31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2340\/0001555572297300","volume":"72","author":"K Hansen","year":"1992","unstructured":"Hansen K, Hovmark A, Lebech A\u2011M, Lebech K, Olsson I, Halkier-S\u00f8rensen L, et al. Roxithromycin in Lyme borreliosis: Discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans. Acta Derm Venereol. 1992;72(4):297\u2013300.","journal-title":"Acta Derm Venereol"},{"key":"1505_CR32","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1086\/516276","volume":"26","author":"D Cadavid","year":"1998","unstructured":"Cadavid D, Barbour AG. Neuroborreliosis during relapsing fever: Review of the clinical manifestations, pathology, and treatment of infections in humans and experimental animals. Clin Infect Dis. 1998;26:151\u201364.","journal-title":"Clin Infect Dis"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-019-1505-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-019-1505-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-019-1505-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T13:18:35Z","timestamp":1694870315000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-019-1505-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,10]]},"references-count":32,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1505"],"URL":"https:\/\/doi.org\/10.1007\/s00508-019-1505-6","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,10]]},"assertion":[{"value":"22 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.P.\u00a0Wormser reports receiving research grants from Immunetics, Inc., Institute for Systems Biology, Rarecyte, Inc., and Quidel Corporation. He owns equity in Abbott\/AbbVie; has been an expert witness in malpractice cases involving Lyme disease; and is an uncompensated board member of the American Lyme Disease Foundation. A.G.\u00a0Barbour reports current receipt of research grants from the National Institutes of Health and the Office of the Assistant Secretary of Defense for Health Affairs, receipt of patent licensing royalties from the University of California for co-inventorship of a method for Lyme disease diagnostic testing, and uncompensated board membership of the American Lyme Disease Foundation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}